Mesenchymal Stem Cells - a Promising Therapy for Acute Respiratory Distress Syndrome

Overview

Journal F1000 Med Rep

Specialty General Medicine

Date 2012 Jan 13

PMID 22238514

Citations 12

Authors

Mairead Hayes

Gerard Curley

John G Laffey

Affiliations

Soon will be listed here.

Abstract

Acute Respiratory Distress Syndrome (ARDS) constitutes a spectrum of severe acute respiratory failure in response to a variety of inciting stimuli that is the leading cause of death and disability in the critically ill. Despite decades of research, there are no therapies for ARDS, and management remains supportive. A growing understanding of the complexity of the pathophysiology of ARDS, coupled with advances in stem cell biology, has lead to a renewed interest in the therapeutic potential of mesenchymal stem cells for ARDS. Recent evidence suggests that mesenchymal stem cells can modulate the immune response to reduce injury and also increase resistance to infection, while also facilitating regeneration and repair of the injured lung. This unique combination of effects has generated considerable excitement. We review the biological characteristics of mesenchymal stem cells that underlie their therapeutic potential for ARDS. We also summarise existing pre-clinical evidence, evaluate the potential and pitfalls of using mesenchymal stem cells for treatment, and examine the likely future directions for mesenchymal stem cells in ARDS.

Citing Articles

Human cell receptors: potential drug targets to combat COVID-19.

Raghav P, Kalyanaraman K, Kumar D Amino Acids. 2021; 53(6):813-842.

PMID: 33950300 PMC: 8097256. DOI: 10.1007/s00726-021-02991-z.

The perivascular origin of pathological fibroblasts.

Di Carlo S, Peduto L J Clin Invest. 2018; 128(1):54-63.

PMID: 29293094 PMC: 5749494. DOI: 10.1172/JCI93558.

Mesenchymal stem cells ameliorate inflammatory cytokine-induced impairment of AT-II cells through a keratinocyte growth factor-dependent PI3K/Akt/mTOR signaling pathway.

Li J, Huang S, Zhang J, Feng C, Gao D, Yao B Mol Med Rep. 2016; 13(5):3755-62.

PMID: 27035760 PMC: 4838139. DOI: 10.3892/mmr.2016.5004.

Lithium enhanced cell proliferation and differentiation of mesenchymal stem cells to neural cells in rat spinal cord.

Dong B, Tu G, Han Y, Chen Y Int J Clin Exp Pathol. 2015; 8(3):2473-83.

PMID: 26045753 PMC: 4440062.

Conditioned media from adipose stromal cells limit lipopolysaccharide-induced lung injury, endothelial hyperpermeability and apoptosis.

Lu H, Poirier C, Cook T, Traktuev D, Merfeld-Clauss S, Lease B J Transl Med. 2015; 13:67.

PMID: 25889857 PMC: 4358867. DOI: 10.1186/s12967-015-0422-3.

References

Rubenfeld G . Epidemiology of acute lung injury. Crit Care Med. 2003; 31(4 Suppl):S276-84. DOI: 10.1097/01.CCM.0000057904.62683.2B. View

Krause D, Theise N, Collector M, Henegariu O, Hwang S, Gardner R . Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001; 105(3):369-77. DOI: 10.1016/s0092-8674(01)00328-2. View

Nauta A, Westerhuis G, Kruisselbrink A, Lurvink E, Willemze R, Fibbe W . Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006; 108(6):2114-20. PMC: 1895546. DOI: 10.1182/blood-2005-11-011650. View

Presneill J, Harris T, Stewart A, Cade J, Wilson J . A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med. 2002; 166(2):138-43. DOI: 10.1164/rccm.2009005. View

Taut F, Rippin G, Schenk P, Findlay G, Wurst W, Hafner D . A Search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest. 2008; 134(4):724-732. DOI: 10.1378/chest.08-0362. View

Sud S, Friedrich J, Taccone P, Polli F, Adhikari N, Latini R . Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med. 2010; 36(4):585-99. DOI: 10.1007/s00134-009-1748-1. View

Lee J, Fang X, Gupta N, Serikov V, Matthay M . Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009; 106(38):16357-62. PMC: 2735560. DOI: 10.1073/pnas.0907996106. View

Iwata K, Doi A, Ohji G, Oka H, Oba Y, Takimoto K . Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med. 2010; 49(22):2423-32. DOI: 10.2169/internalmedicine.49.4010. View

Tang B, Craig J, Eslick G, Seppelt I, McLean A . Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med. 2009; 37(5):1594-603. DOI: 10.1097/CCM.0b013e31819fb507. View

10.

Ren G, Su J, Zhang L, Zhao X, Ling W, Lhuillie A . Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009; 27(8):1954-62. DOI: 10.1002/stem.118. View

11.

Weiss D, Kolls J, Ortiz L, Panoskaltsis-Mortari A, Prockop D . Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc. 2008; 5(5):637-67. PMC: 2645238. DOI: 10.1513/pats.200804-037DW. View

12.

Fang X, Neyrinck A, Matthay M, Lee J . Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem. 2010; 285(34):26211-22. PMC: 2924032. DOI: 10.1074/jbc.M110.119917. View

13.

Hare J, Traverse J, Henry T, Dib N, Strumpf R, Schulman S . A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54(24):2277-86. PMC: 3580848. DOI: 10.1016/j.jacc.2009.06.055. View

14.

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

15.

Brower R, Matthay M, Morris A, Schoenfeld D, Thompson B, Wheeler A . Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342(18):1301-8. DOI: 10.1056/NEJM200005043421801. View

16.

Wiedemann H, Wheeler A, Bernard G, Thompson B, Hayden D, deBoisblanc B . Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006; 354(24):2564-75. DOI: 10.1056/NEJMoa062200. View

17.

Matthay M, Brower R, Carson S, Douglas I, Eisner M, Hite D . Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011; 184(5):561-8. PMC: 3175548. DOI: 10.1164/rccm.201012-2090OC. View

18.

Stapleton R, Wang B, Hudson L, Rubenfeld G, Caldwell E, Steinberg K . Causes and timing of death in patients with ARDS. Chest. 2005; 128(2):525-32. DOI: 10.1378/chest.128.2.525. View

19.

Nauta A, Fibbe W . Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007; 110(10):3499-506. DOI: 10.1182/blood-2007-02-069716. View

20.

Curley G, Hayes M, Ansari B, Shaw G, Ryan A, Barry F . Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax. 2011; 67(6):496-501. DOI: 10.1136/thoraxjnl-2011-201059. View